Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
NeuroQ Review: The Right Study, Missing The Key Number
NeuroQ is a memory supplement formulated with Dr Dale Bredesen, sold from $34.97 to $89.95 a bottle depending on commitment. It does several things almost no supplement brand does: it discloses every dose, it ran a double-blind placebo-controlled trial on the complete formula rather than citing studies on one ingredient, it states that the trial was company-sponsored, and it offers a 60-day refund even if the bottle is empty. Then, having run a placebo-controlled trial, it publishes only what happened to the people who took the supplement.
Our Verdict
NeuroQ by LifeSeasons · neuroq.com · $34.97–$89.95 per bottle
They tested the actual formula, which almost nobody does
The standard trick in this industry is to cite a study on one ingredient, usually at a dose the product does not contain, and let the reader assume the finished product inherits the result. NeuroQ explicitly rejects that: the actual formula was tested in a 90-day, double-blind, placebo-controlled trial, and the site says in terms not just one ingredient with a study attached. That is the correct design on the correct product, and it is rarer than it should be.
And then published only half of it
The reported results — 97% of participants improving, plus percentile gains of 10% processing speed, 7% working memory and 12% executive function — are all treatment-arm figures. The placebo arm's numbers appear nowhere. The entire purpose of a placebo-controlled trial is the comparison between groups, and it is the one thing not shown. They possess the number that would settle this. They have chosen not to print it.
Repeated cognitive tests improve on their own
This is why the missing arm matters rather than being a technicality. Take a computerised cognitive battery repeatedly over 90 days and your scores rise because you have learned the test. That practice effect is well established and is precisely the reason these trials are controlled. A 97% improvement rate within the first seven days is exactly the shape practice effects produce — and 97% counts anyone improving on any one of three domains, which is a very easy bar to clear.
Every dose disclosed, and the sponsorship admitted
Gotu kola 250 mg, turmeric 250 mg, ginkgo biloba 120 mg, phosphatidylserine 100 mg, coffee fruit extract 100 mg, bee propolis 75 mg. No proprietary blend hiding the quantities. The site also footnotes that the study was company-sponsored rather than letting readers assume independence, states third-party batch testing and GMP manufacture, and carries the DSHEA disclaimer. That is a materially more honest presentation than most of this category manages.
A 60-day guarantee that survives you opening the bottle
Sixty days, money back, even if the bottle is empty — and cancellation explicitly requires no phone call, with an email route published. We have spent this year documenting guarantees that void the moment you open the packaging, which makes them worthless for judging whether a product works. This is the opposite, and it is the single most consumer-friendly term we have found in the supplement category.
A frightened audience, and a 2.6-fold price spread
A bottle costs $89.95 one-time, $69.95 subscribed monthly, $46.63 on a three-month plan, or $34.97 if you commit to six months up front. The cheapest price requires the longest commitment, which is the standard structure — but this is a product marketed to people frightened about memory loss, sold partly through television and phone lines, and the gap between casual and committed pricing is 2.6 times.
Our Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
6 / 6
Ingredients with disclosed doses
0
Placebo-arm results published
7–12%
Percentile domain gains, treatment arm
60 days
Refund window, even if empty
One missing column
1. What a placebo-controlled trial is for
When a trial is placebo-controlled, half the participants receive something inert. Both groups are measured identically. The finding is never what happened to the treatment group — it is the gap between the two. Everything that is not the drug affects both arms equally: expectation, regression to the mean, seasonal variation, being watched, and, in cognitive research, getting better at the test.
NeuroQ reports that 97% of participants improved in memory, focus or concentration within the first seven days, with average percentile gains over the full study of 10% in processing speed, 7% in working memory and 12% in executive function. Those are real, specific numbers and more granular than most supplement marketing offers. They are also, every one of them, describing only the people who took NeuroQ.
The question a reader needs answered is simple: what happened to the placebo group? If placebo participants improved by 9% on processing speed and NeuroQ participants by 10%, the supplement contributed almost nothing. If placebo improved 2% and NeuroQ 10%, that is a meaningful result worth paying for. The company ran the comparison — that is what placebo-controlled means — and has the answer. It is not on the page.
2. The practice effect, and why 97% is the weakest number on the page
Computerised neurocognitive batteries measure things like reaction time, working memory span and task switching. Do one repeatedly and you improve at it, because you have learned the format, the rhythm and the strategy. This practice effect is one of the best-documented confounders in cognitive research and is the specific reason these studies require control groups.
Now consider the headline: 97% of participants saw improvement in memory, focus, or concentration in the first seven days. Three domains, any one qualifying, measured a week apart. Nearly everyone will move upward on at least one of three measures over seven days, whatever they swallowed. It is the largest number on the page and it carries the least information — and it is doing the most work in persuading someone to spend $209.85.
The percentile domain figures deserve more respect. Gains of 7 to 12% in specific measured domains over 90 days are the sort of thing a real effect might look like. They are also, notably, far more modest than 97% implies — and a reader who sees the big number first will not naturally scale their expectations down to the small ones. We would also note that no peer-reviewed publication or trial registration is cited anywhere we looked, so the study cannot be read independently.
3. Dr Bredesen: real credentials, contested protocol
It would be easy and wrong to wave this away as celebrity-doctor branding. Dale Bredesen is a genuine neurologist with more than three decades researching neurodegeneration at UCLA and the Buck Institute, and The End of Alzheimer's is a widely read book. Those credentials are not in dispute and the site describes them accurately.
What is in dispute is the framework. The ReCODE protocol, and the broader claim that cognitive decline in Alzheimer's can be reversed through a multi-factor programme, has met sustained scepticism in mainstream neurology — chiefly because the supporting publications have been uncontrolled case series rather than randomised trials, making it impossible to separate the intervention from selection and natural variation. That is the same methodological objection we are making about the 97% figure, which is a consistency worth noticing.
The site also organises the product around addressing all four primary causes of age-associated mental decline — neurotransmitter health, neuron health, cerebral blood flow and inflammation. That is a tidy framing rather than a settled scientific consensus; cognitive ageing is not agreed to have exactly four causes. The individual ingredients are reasonable choices within that story: ginkgo at 120 mg is a conventionally studied dose, phosphatidylserine at 100 mg sits within the range used in research, and turmeric and gotu kola are standard inclusions.
4. What to do if memory is actually your worry
This is the part that matters more than the review. If you or someone close to you has noticed genuine memory change, the first move is a clinical assessment, not a supplement — because a meaningful proportion of cognitive complaints have causes that can be treated. Thyroid dysfunction, B12 deficiency, depression, sleep apnoea, medication side effects and alcohol all produce cognitive symptoms and all respond to being addressed.
Sleep apnoea deserves a specific mention on this site, because it is strongly associated with higher body weight, frequently undiagnosed, and a well-recognised cause of daytime cognitive impairment. Someone carrying extra weight, sleeping badly and worrying about their memory has a plausible and treatable explanation available before any supplement is considered.
On the GLP-1 question: semaglutide is currently in phase 3 trials for early Alzheimer's disease, which reflects real scientific interest in the metabolic contribution to cognitive decline. But a drug under investigation is not a drug shown to work, and we apply that standard evenly — it is the same objection we have made to NeuroQ's evidence on this page. Neither is a reason to skip the appointment.
Pricing, and the commitment ladder
| Plan | Price | Per bottle | Commitment |
|---|---|---|---|
| One-time single bottle | ~$89.95 | $89.95 | None |
| 1 month subscription | $69.95 | $69.95 | Every 30 days |
| 3 months | $139.90 | $46.63 | Every 90 days |
| 6 months | $209.85 | $34.97 | Every 180 days |
The 60-day guarantee changes how to read this table. Because a refund is available even on an empty bottle, the six-month bundle at $34.97 a bottle is less risky than commitment pricing usually is — you can take it, use it, and ask for your money back inside the window if nothing happens. That is a genuinely unusual position for a supplement buyer to be in, and it is the strongest argument the company has.
In its favour
- Ran a double-blind, placebo-controlled trial on the complete formula, not on a single ingredient.
- Every ingredient dosed and disclosed — no proprietary blend concealing quantities.
- Discloses that the study was company-sponsored rather than implying independence.
- Reports specific percentile domain outcomes (7 to 12%) rather than only a headline percentage.
- 60-day money-back guarantee valid even if the bottle is empty — the most consumer-friendly term we have seen in this category.
- Cancellation explicitly requires no phone call, with an email route published.
- Third-party batch testing, GMP-certified facility, US manufacture.
- DSHEA disclaimer present, and a simulated chart is footnoted as simulated.
- Formulator's credentials are real and described accurately.
Against it
- No placebo-arm results published anywhere — the comparison the trial exists to produce.
- The 97% headline is a three-domain composite over seven days, the interval most vulnerable to practice effects.
- No peer-reviewed publication, journal, authors or trial registration cited for the study.
- The four causes of cognitive decline framing is presented as settled science when it is a model.
- The underlying Bredesen protocol remains contested in mainstream neurology on methodological grounds.
- $34.97 to $89.95 a bottle — expensive, with the best price requiring six months upfront.
- Marketed via television and phone lines to an older audience worried about dementia.
- A supplement cannot rule out the treatable causes of memory change; only assessment can.
Our verdict: 3.2 out of 5
A supplement company that did the difficult, expensive, correct thing — and then reported its results in the one way that makes them impossible to evaluate.
We want to give credit properly here, because it is unusual. Most brain supplements are a proprietary blend, an ingredient study performed at a dose the product does not contain, and a paragraph of adjectives. NeuroQ discloses all six ingredients with milligram figures, ran a double-blind placebo-controlled trial on the finished formula rather than borrowing someone else's ingredient data, tells you the study was company-sponsored, publishes specific domain-level outcomes, and refunds you within 60 days even if you have finished the bottle. On process, this is the best-behaved supplement brand we have reviewed this year.
Which makes the omission harder to explain, not easier. They ran a placebo-controlled trial. That means they have two sets of numbers. They published one. Every figure on the page — 97% improved, 10% processing speed, 7% working memory, 12% executive function — describes only the people who took NeuroQ. The placebo group's results, the comparison the entire study exists to generate, appear nowhere we could find.
That gap matters most because of what is being measured. Repeated computerised cognitive testing improves scores through practice alone, reliably and substantially. A 97% improvement rate across three domains in seven days is precisely the pattern practice effects produce. It might also be a real effect. Nobody reading the page can tell, and the company could resolve it in one sentence.
On Dr Bredesen we have tried to be fair. His credentials are genuine and the site represents them accurately. His broader protocol is contested in mainstream neurology for the same reason we are questioning the 97% figure — reliance on uncontrolled data — and a reader deserves both halves of that picture rather than either alone.
So: 3.2, which is a real score for a company doing many things right. If you want to try it, the 60-day empty-bottle guarantee genuinely de-risks the six-month bundle at $34.97 a bottle, and we would take that over the $89.95 single. But if you are here because your memory has actually changed, buy the appointment first. Thyroid disease, B12 deficiency, depression, medication effects and sleep apnoea all cause cognitive symptoms and all can be treated — and sleep apnoea in particular is common, underdiagnosed and strongly linked to higher body weight. No supplement rules any of them out.
Frequently asked questions
What is NeuroQ and what is in it?
A memory and focus supplement from LifeSeasons, formulated with Dr Dale Bredesen. The panel is fully disclosed with doses: gotu kola 250 mg, turmeric 250 mg, ginkgo biloba 120 mg, phosphatidylserine 100 mg, coffee fruit extract 100 mg and bee propolis 75 mg. Full dose transparency is genuinely uncommon in this category and we credit it — you can evaluate what you are buying.
Did they really run a clinical trial?
Yes, and on the right thing. Most supplement marketing cites studies on a single ingredient, often at a dose the product does not contain. NeuroQ states it tested the complete formula in a 90-day, double-blind, placebo-controlled trial using computerised neurocognitive testing, and says so explicitly: not just one ingredient with a study attached. That is the correct study design applied to the correct product, and it puts them ahead of nearly every competitor we have reviewed.
So what is the problem?
They published the treatment arm and not the placebo arm. The results given are 97% of participants improving in memory, focus or concentration, plus average percentile gains of 10% processing speed, 7% working memory and 12% executive function. Every one of those is a treatment-group number. In a placebo-controlled trial the meaningful figure is the difference between the groups, and the placebo group's results are not published anywhere we could find. They ran the comparison. They did not report it.
Why does the placebo arm matter so much here?
Because repeated cognitive testing improves scores on its own. Take the same computerised battery several times over 90 days and you get better at it — a practice effect, well documented and precisely why cognitive trials need controls. A 97% improvement rate in the first seven days is exactly what practice effects would produce. Without knowing whether the placebo group also improved 97%, or by 9% on processing speed against the treatment group's 10%, the numbers cannot tell you whether the supplement did anything.
Is the 97% figure meaningful?
It is the weakest number on the page, despite being the largest. It counts anyone who improved in memory, focus or concentration — improvement on any one of three domains qualifies. Broad composite endpoints like that are easy to hit by chance alone across three measures. The percentile domain figures of 7 to 12% are more informative because they are specific, and they are also considerably more modest than 97% suggests to a casual reader.
Who is Dr Dale Bredesen?
A genuinely credentialed neurologist with more than 30 years researching neurodegeneration at UCLA and the Buck Institute, and author of The End of Alzheimer's. His credentials are real. His ReCODE protocol and the claim that cognitive decline in Alzheimer's can be reversed remain contested in mainstream neurology, largely because the supporting publications have been uncontrolled case series rather than randomised trials. Both things are true at once, and a reader should know both.
What does it cost?
Substantially more than most supplements, and the price depends heavily on commitment. One month subscribed is $69.95, three months is $139.90 at $46.63 a bottle, and six months is $209.85 at $34.97 a bottle. That is a 2.6-fold spread between the cheapest and dearest per-bottle price, and the cheapest requires committing to half a year up front. A one-time single bottle runs around $89.95.
Is there a GLP-1 connection?
A live research question rather than an established one. Semaglutide is being studied in phase 3 trials for early Alzheimer's disease, which reflects genuine scientific interest in metabolic contributions to cognitive decline. But a drug being trialled for a condition is not evidence that it treats it — which is the same standard we are applying to NeuroQ on this page. If cognitive symptoms concern you, that belongs with a clinician who can rule out the treatable causes rather than with either purchase.
See a clinician first, then decide
If memory change is real, get the treatable causes ruled out before spending anything. If you then want to try NeuroQ, the 60-day empty-bottle refund is genuine and makes the longer bundle the sensible option. We earn 35% — around $73 on the six-month plan — which is why the advice to see a doctor comes first.
View NeuroQ (affiliate link)Prices, doses and claims verified 11 August 2026 and subject to change.
Compare Other GLP-1 Providers
See how other telehealth providers stack up.
Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →Amazon One Medical
Brand-Name, No CompoundingFDA-approved Wegovy, Zepbound and Foundayo from $149/month cash, $25 with insurance and $50/month for eligible Medicare members — the first mainstream route to approved medication at prices that compete with compounded. We earn no commission from it
Read Review →GoodRx Care
Trusted BrandTelehealth platform from GoodRx with transparent pricing and established trust
Read Review →PlushCare
Insurance AcceptedMajor telehealth platform with brand-name FDA-approved GLP-1s, insurance support, and 1M+ members treated
Read Review →Medical disclaimer
This review is informational journalism about a supplement and its published claims. It is not medical advice, not a diagnosis, and not a treatment recommendation. Dietary supplements are not FDA-approved and nothing described here is intended to diagnose, treat, cure or prevent any disease, including Alzheimer's disease or any form of dementia. New or worsening memory problems require assessment by a clinician: several causes of cognitive symptoms — including thyroid dysfunction, vitamin B12 deficiency, depression, medication effects, alcohol and obstructive sleep apnoea — are treatable, and delay costs time that matters. Ginkgo biloba may increase bleeding risk and interacts with anticoagulant and antiplatelet medication; discuss any supplement with a doctor or pharmacist before starting, particularly if you take prescription medicines or are due surgery. Semaglutide is under investigation in trials for early Alzheimer's disease; being studied for a condition is not evidence of benefit in it.
Sources · date reviewed: 11 August 2026
- neuroq.com homepage and neuroq.com/products/memory-focus — retrieved 11 August 2026. Source for the ingredient panel and doses (gotu kola 250 mg, turmeric 250 mg, ginkgo biloba 120 mg, phosphatidylserine 100 mg, coffee fruit extract 100 mg, bee propolis 75 mg); the four-causes framing; the trial description as a 90-day double-blind placebo-controlled study on the complete formula using computerised neurocognitive testing; the reported outcomes of 97% of participants improving in memory, focus or concentration in the first seven days and average percentile domain gains of 10% processing speed, 7% working memory and 12% executive function; and the footnote describing the study as company-sponsored.
- Same pages — source for pricing: one month subscription $69.95, three months $139.90 at $46.63 per bottle, six months $209.85 at $34.97 per bottle, with a one-time single bottle around $89.95; the 60-day money-back guarantee stated as valid even if the bottle is empty; the statement that no phone call is required to cancel; third-party batch testing, GMP-certified facility and US manufacture; and the DSHEA disclaimer.
- neuroq.com/products.json?limit=250 — retrieved 11 August 2026, ten products enumerated with prices from $24.99 to $431.73 across the range including Memory & Focus, Memory & Focus Extra Strength, Memory DHA-400, Calm Focus, Sleep Now and a multivitamin.
- We searched the pages for placebo-arm results, a journal name, authors, a DOI or a trial registration number and found none. Our criticism is that the comparison group's outcomes are not published, not that the trial did not occur.
- Practice effects — improvement in repeated neuropsychological and computerised cognitive testing arising from familiarity with the test rather than from any intervention — are a long-established confounder and the principal reason cognitive trials require control groups.
- Dr Dale Bredesen is a neurologist who researched neurodegeneration at UCLA and the Buck Institute and authored The End of Alzheimer's. The ReCODE protocol associated with him has been criticised within mainstream neurology on the grounds that supporting publications have been uncontrolled case series rather than randomised controlled trials.
- Semaglutide is being evaluated in phase 3 trials in early Alzheimer's disease. We report this as ongoing research and draw no conclusion about efficacy.
- Katalys offer listing #1438, retrieved 11 August 2026 — 35.00% commission, United States targeting, sub-network Impact.
We did not purchase or test the product, and we did not obtain or review the underlying study, which we could not locate in published form. We did not contact the company before publishing, and we would revise this page promptly if placebo-arm results or a peer-reviewed publication were released.
Affiliate disclosure
GLP1Drugs.org earns a 35% commission on orders placed through the links on this page — approximately $73 on the six-month bundle, among the highest rates we carry, from a product marketed to people worried about memory loss. We have rated NeuroQ 3.2 out of 5, credited the parts it does better than its competitors, and led with the missing placebo comparison. No company reviewed here sees or approves our copy before publication.